Zepzelca (active pTAP negotiation) (lurbinectedin)

pCPA File Number: 23501

Negotiation Status:

Active Negotiation

Indication(s):

For the treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy.

Sponsor/Manufacturer:

Jazz Pharmaceuticals Canada Inc.

CDA-AMC Project Number:

PC0431-000

pCPA Engagement Letter Issued:

2026-02-25

Negotiation Process Concluded:

Not Applicable